Drug
Edp 322
Edp 322: highest development phase Phase 1, developed by Enanta Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-322 NCT00990145 | Phase 1 | MRSA, SSTI |
| EDP-322 NCT00989872 | Phase 1 | Skin and Soft Tissue Infections |
Latest
No recent events.
Follow Edp 322 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.